H

Hospital La Arruzafa | Cordoba, Spain

Research site

(Unclaimed)

Location

Avenida de la Arruzafa 9, Córdoba, Córdoba, Spain

Site insights

Top conditions

Top treatments

GT005

VRDN-001

Zimura

Teprotumumab

VRDN 001

Ripasudil

VRDN-003

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 14 total trials

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Enrolling

Thyroid Eye Disease (TED)

Drug: VRDN-003

Drug: Placebo

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. (UplighTED)

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod P...

Enrolling

Thyroid Eye Disease

Combination Product: Efgartigimod PH20 SC

Other: Placebo PH20 SC

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Active, not recruiting

Fuchs Endothelial Corneal Dystrophy

Drug: Ripasudil

Drug: Placebo

Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. (CELOPHIN)

A phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC...

Active, not recruiting

Pemphigoid

Lyell Syndrome

Drug: Double Dose

Drug: Single Dose

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting

Thyroid Eye Disease

Drug: Teprotumumab

Drug: Placebo